Expand all sections

Ipilimumab

Yervoy

Extended indication Extension of indication to include in combination with nivolumab the treatment of adolescents (12 ye
Therapeutic value No estimate possible yet
Registration phase Registered and reimbursed

Product

Active substance Ipilimumab
Domain Oncology
Reason of inclusion Indication extension
Main indication Skin cancer
Extended indication Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma.
Proprietary name Yervoy
Manufacturer BMS
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date September 2022
Expected Registration June 2023
Orphan drug No
Registration phase Registered and reimbursed
Additional remarks Handelsvergunning per 31 mei 2023

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

Patient volume

< 5

Market share is generally not included unless otherwise stated.
References Expertopinie;
Additional remarks Het betreft een indicatieuitbreiding voor 12 tot 18 jaar. Op basis van een expertopinie wordt er verwacht dat er maximaal 5 patiënten in aanmerking zullen komen voor deze indicatie.

Expected cost per patient per year

References G-standaard
Additional remarks Nivolumab 10mg/ml flacon, 4 ml (40mg): €405,03; Nivolumab 10mg/ml flacon, 10ml (100mg): €1.012,56; Nivolumab 10mg/ml flacon, 24ml (240mg): €2.430,15; Z-index, 1 april 2021, exclusief btw de prijs is ingeschat in lijn met andere indicaties. Voor alle indicatie van nivolumab geldt een financieel arrangement die is voortgekomen uit de onderhandelingen in de sluis lopend tot 1 januari 2027. (Bron:https://zoek.officielebekendmakingen.nl/stcrt-2023-30299.html) Ipilimumab 5mg/ml, flacon 10ML (50mg): €3.268,50; Ipilimumab 5mg/ml, flacon 40ML (200mg): €1.3074. Z-index, 1 april 2021, exclusief btw.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.